Anton Kraxner
Research Subjects
Anton Kraxner has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Jehad Charo
F. Hoffmann-La Roche AG, Pharmaceutical Research and Early Development Oncology, Roche Innovation Center Zurich, Zurich, Switzerland
60 shared publications - Volker Teichgräber
17Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center, Basel, Switzerland
60 shared publications - David Dejardin
Product Development, Data Sciences, F. Hoffmann-La Roche AG, Basel, Switzerland
59 shared publications - Caroline Ardeshir
21F. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom
40 shared publications - Christophe Boetsch
Roche Innovation Center Basel (RICB), Basel, Switzerland
40 shared publications - Hans Prenen
Universitair Ziekenhuis Antwerpen, Edegem, Belgium
40 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma
Supplementary Figure S2. Additional pharmacodynamic results.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma
Supplementary Figure S2. Additional pharmacodynamic results.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma
Supplementary Figure S3. Pharmacodynamic changes and associated clinical outcomes.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma
Supplementary Figure S3. Pharmacodynamic changes and associated clinical outcomes.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods S1 from Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma
Supplementary Methods. Includes Eligibility criteria for the clinical study, Study Treatment, DLT Criteria, Tumor Response Assessment, and Pharmacodynamic Methods.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods S1 from Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma
Supplementary Methods. Includes Eligibility criteria for the clinical study, Study Treatment, DLT Criteria, Tumor Response Assessment, and Pharmacodynamic Methods.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma
Supplementary Table S3. Characterization of patients with partial response.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma
Supplementary Table S3. Characterization of patients with partial response.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma
Supplementary Table S2. Overview of adverse events.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma
Supplementary Table S2. Overview of adverse events.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma
Supplementary Figure S1. Flow chart.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma
Supplementary Figure S1. Flow chart.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma
Supplementary Table S1. Representativeness of study participants.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma
Supplementary Table S1. Representativeness of study participants.
- Open Access
- 24 February 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma
Antitumor activity per RECIST version 1.1
- 24 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma
Antitumor activity per RECIST version 1.1
- Open Access
- 24 February 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma
Antitumor activity following treatment with FAP-IL2v of CPI-experienced patients in the extension part with at least one postbaseline tumor assessment (n = 62). Best percentage change in the sum of diameters of target lesion from baseline (column color indicates confirmed best overall response) in CPI-experienced patients in the Q3W extension part (n = 41; A) and in the QW/Q3W extension part (n = 21; B). C, Kaplan–Meier estimate of progression-free survival in patients in the Q3W (blue) and QW/Q3W (red) extension part. Tick marks on the Kaplan–Meier plot show censoring of the data at the last time the patient was known to be alive. NE, not evaluable; PD, progressive disease; SD, stable disease; SLD, sum of longest diameters.
- 24 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma
Antitumor activity following treatment with FAP-IL2v of CPI-experienced patients in the extension part with at least one postbaseline tumor assessment (n = 62). Best percentage change in the sum of diameters of target lesion from baseline (column color indicates confirmed best overall response) in CPI-experienced patients in the Q3W extension part (n = 41; A) and in the QW/Q3W extension part (n = 21; B). C, Kaplan–Meier estimate of progression-free survival in patients in the Q3W (blue) and QW/Q3W (red) extension part. Tick marks on the Kaplan–Meier plot show censoring of the data at the last time the patient was known to be alive. NE, not evaluable; PD, progressive disease; SD, stable disease; SLD, sum of longest diameters.